vTv Therapeutics (NASDAQ:VTVT) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Several other research firms have also recently commented on VTVT. Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Roth Mkm initiated coverage on vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price on the stock. BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a report on Wednesday, March 11th. Finally, Evercore began coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Price Performance

Shares of VTVT opened at $38.43 on Wednesday. The stock has a market cap of $151.41 million, a price-to-earnings ratio of -41.32 and a beta of 0.26. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The company has a 50-day moving average of $35.96 and a two-hundred day moving average of $34.07.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million. Analysts anticipate that vTv Therapeutics will post -2.66 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Baker BROS. Advisors LP increased its position in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the period. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics in the 4th quarter valued at $221,000. Finally, 683 Capital Management LLC bought a new stake in vTv Therapeutics in the 4th quarter valued at $731,000. 17.51% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.